About LIDODERM

LIDODERM (lidocaine patch 5%), is a topical therapy that works directly at the site of postherpetic neuralgia (PHN) pain and is backed by more than a decade of use. LIDODERM is the first and only lidocaine-based topical medication approved by the FDA for the treatment of pain associated with PHN, and offers you and your patients a custom fit for managing PHN pain.

A first-line therapy, alone or with oral analgesics1,2,3

  • Works directly at the site of pain4-6

Proven efficacy in 2 randomized, placebo-controlled clinical trials (N=67)4,7,8

  • In the first study, patients felt significant pain relief at 30 minutes after the first dose vs observation cohort7
  • In the second study, 84% of PHN patients had moderate to complete pain relief at 2 weeks8
  • LIDODERM (lidocaine patch 5%) may take up to 2 weeks to achieve the best outcome4,8

Efficacy of lidocaine patch 5% reaffirmed in a European clinical trial in PHN9

  • Patients remained on lidocaine patch 5% more than twice as long as placebo (median time to exit was 14 days vs 6 days; P=0.0398 per protocol population)

Demonstrated favorable safety profile and generally well tolerated4,10,7

  • No serious adverse events in clinical trials7,10
  • Low risk of drug-drug interactions; in clinical trials, patients used concomitant analgesics7,10
  • Use with caution in patients receiving Class 1 antiarrhythimics

Customized application for your patients with PHN pain4

  • A simple application in your office, or at home by your patients
  • Patches can be cut to custom fit the areas of pain

Patients can wear up to 3 patches simultaneously for 12 hours, followed by 12 hours off

Applied to the site of localized pain, the targeted peripheral analgesia of lidocaine is thought to penetrate the dermis, bind to sodium channels, and stabilize neuronal activity, reducing painful impulses and the potential for central sensitization.4, 5, 6

Applied in clinical trials, LIDODERM provided significant on-site efficacy (as measured by visual analog, neuropathic, and verbal pain scales).7,10
Read more about LIDODERM efficacy

Applied to intact skin, LIDODERM uses topical technology to deliver analgesia with minimal systemic effect and low risk of serious adverse events.4
Obtain safety data

Applied in the office, LIDODERM allows you and your PHN patients to immediately get "hands-on" with localized pain — targeting right at the site of pathology.4
Learn more about dosing

LIDODERM is recommended for localized pain of PHN by respected third parties, used alone or with oral analgesics.1,2,3,6
Find out more about third party recommendations


References

  1. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
  2. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
  3. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-965.
  4. LIDODERM Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2010.
  5. Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today's Therapeutic Trends. 2000;18:1-20.
  6. Argoff CE. Targeted topical peripheral analgesics in the management of pain. Curr Pain Headache Rep. 2003;7(1):34-38.
  7. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39-44.
  8. Data on file, DOF-LD-02, Endo Pharmaceuticals.
  9. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393-408.
  10. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533-538.